Renaissance Technologies LLC Sells 239,916 Shares of Sana Biotechnology, Inc. $SANA

Renaissance Technologies LLC cut its stake in shares of Sana Biotechnology, Inc. (NASDAQ:SANA) by 14.2% in the 1st quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 1,451,200 shares of the company’s stock after selling 239,916 shares during the period. Renaissance Technologies LLC owned about 0.52% of Sana Biotechnology worth $4,179,000 as of its most recent SEC filing.

Several other hedge funds also recently modified their holdings of the company. Balyasny Asset Management L.P. bought a new stake in Sana Biotechnology during the 4th quarter worth $6,834,000. Vanguard Group Inc. raised its position in Sana Biotechnology by 19.9% in the third quarter. Vanguard Group Inc. now owns 9,128,973 shares of the company’s stock valued at $32,408,000 after purchasing an additional 1,517,474 shares during the last quarter. JPMorgan Chase & Co. boosted its stake in shares of Sana Biotechnology by 180.8% during the third quarter. JPMorgan Chase & Co. now owns 2,135,444 shares of the company’s stock valued at $7,581,000 after purchasing an additional 1,375,029 shares in the last quarter. State Street Corp boosted its stake in shares of Sana Biotechnology by 20.6% during the fourth quarter. State Street Corp now owns 8,054,841 shares of the company’s stock valued at $32,783,000 after purchasing an additional 1,374,300 shares in the last quarter. Finally, Integral Health Asset Management LLC grew its holdings in shares of Sana Biotechnology by 50.0% during the fourth quarter. Integral Health Asset Management LLC now owns 3,000,000 shares of the company’s stock worth $12,210,000 after purchasing an additional 1,000,000 shares during the last quarter. Institutional investors and hedge funds own 88.23% of the company’s stock.

Sana Biotechnology Price Performance

Shares of SANA opened at $3.52 on Friday. The business has a 50-day moving average of $3.30 and a 200-day moving average of $3.49. The company has a market capitalization of $979.58 million, a price-to-earnings ratio of -3.78 and a beta of 2.16. Sana Biotechnology, Inc. has a 1 year low of $2.61 and a 1 year high of $6.55.

Sana Biotechnology (NASDAQ:SANA) last announced its earnings results on Monday, May 11th. The company reported ($0.14) EPS for the quarter, beating the consensus estimate of ($0.15) by $0.01. As a group, sell-side analysts anticipate that Sana Biotechnology, Inc. will post -0.59 EPS for the current year.

Wall Street Analyst Weigh In

Several research firms have recently issued reports on SANA. Weiss Ratings raised Sana Biotechnology from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Thursday, July 23rd. Wall Street Zen lowered shares of Sana Biotechnology from a “hold” rating to a “sell” rating in a report on Monday, July 20th. Wedbush upped their price target on shares of Sana Biotechnology from $6.00 to $7.00 and gave the company an “outperform” rating in a research report on Tuesday, April 14th. Finally, Rodman & Renshaw started coverage on shares of Sana Biotechnology in a research note on Monday, May 11th. They set a “buy” rating and a $16.00 price target for the company. Seven research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $9.50.

Sana Biotechnology Profile

Sana Biotechnology is a clinical-stage biopharmaceutical company focused on the development of engineered cells as medicines with the goal of treating a broad range of diseases. The company applies advanced gene editing and gene delivery technologies to create next-generation cell therapy products for oncology, genetic disorders and other serious diseases. By leveraging both ex vivo and in vivo approaches, Sana aims to repair or replace damaged cells and restore healthy tissue function.

The company’s core platform integrates proprietary gene writing capabilities alongside established gene editing tools such as CRISPR–Cas9.